212 related articles for article (PubMed ID: 30482241)
1. Gain of UBE2D1 facilitates hepatocellular carcinoma progression and is associated with DNA damage caused by continuous IL-6.
Zhou C; Bi F; Yuan J; Yang F; Sun S
J Exp Clin Cancer Res; 2018 Nov; 37(1):290. PubMed ID: 30482241
[TBL] [Abstract][Full Text] [Related]
2. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation.
Sun J; Zhu Z; Li W; Shen M; Cao C; Sun Q; Guo Z; Liu L; Wu D
J Exp Clin Cancer Res; 2020 Oct; 39(1):222. PubMed ID: 33087136
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
[TBL] [Abstract][Full Text] [Related]
4. UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma.
Pan YH; Yang M; Liu LP; Wu DC; Li MY; Su SG
Biochem Biophys Res Commun; 2018 Sep; 503(2):895-902. PubMed ID: 29928880
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of ubiquitin-conjugating enzyme E2Z is associated with human hepatocellular carcinoma.
Shi X; Wang B; Chen X; Zheng Y; Ding Y; Wang C
Biochem Biophys Res Commun; 2020 Feb; 523(1):25-32. PubMed ID: 31831168
[TBL] [Abstract][Full Text] [Related]
6. NOXIN as a cofactor of DNA polymerase-primase complex could promote hepatocellular carcinoma.
Zhang ZZ; Huang J; Wang YP; Cai B; Han ZG
Int J Cancer; 2015 Aug; 137(4):765-75. PubMed ID: 25612832
[TBL] [Abstract][Full Text] [Related]
7. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Wang K; Lim HY; Shi S; Lee J; Deng S; Xie T; Zhu Z; Wang Y; Pocalyko D; Yang WJ; Rejto PA; Mao M; Park CK; Xu J
Hepatology; 2013 Aug; 58(2):706-17. PubMed ID: 23505090
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin-conjugating enzyme E2T knockdown suppresses hepatocellular tumorigenesis
Guo J; Wang M; Wang JP; Wu CX
World J Gastroenterol; 2019 Nov; 25(43):6386-6403. PubMed ID: 31798276
[TBL] [Abstract][Full Text] [Related]
9. Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis.
Chung YL; Wu ML
J Pathol; 2013 Aug; 230(4):377-87. PubMed ID: 23620081
[TBL] [Abstract][Full Text] [Related]
10. UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53.
Liu LP; Yang M; Peng QZ; Li MY; Zhang YS; Guo YH; Chen Y; Bao SY
Biochem Biophys Res Commun; 2017 Nov; 493(1):20-27. PubMed ID: 28935368
[TBL] [Abstract][Full Text] [Related]
11. PCNA-associated factor (KIAA0101/PCLAF) overexpression and gene copy number alterations in hepatocellular carcinoma tissues.
Tantiwetrueangdet A; Panvichian R; Sornmayura P; Leelaudomlipi S; Macoska JA
BMC Cancer; 2021 Mar; 21(1):295. PubMed ID: 33743635
[TBL] [Abstract][Full Text] [Related]
12. Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.
Wei S; Xiong M; Zhan DQ; Liang BY; Wang YY; Gutmann DH; Huang ZY; Chen XP
Carcinogenesis; 2012 Mar; 33(3):538-47. PubMed ID: 22226916
[TBL] [Abstract][Full Text] [Related]
13. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Zhang ZY; Hong D; Nam SH; Kim JM; Paik YH; Joh JW; Kwon CH; Park JB; Choi GS; Jang KY; Park CK; Kim SJ
J Hepatol; 2015 Jan; 62(1):121-30. PubMed ID: 25131770
[TBL] [Abstract][Full Text] [Related]
14. Upregulated expression of ubiquitin-conjugating enzyme E2Q1 (UBE2Q1) is associated with enhanced cell proliferation and poor prognosis in human hapatocellular carcinoma.
Chang R; Wei L; Lu Y; Cui X; Lu C; Liu L; Jiang D; Xiong Y; Wang G; Wan C; Qian H
J Mol Histol; 2015 Feb; 46(1):45-56. PubMed ID: 25311764
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma.
Guo X; Yang M; Gu H; Zhao J; Zou L
Cancer Epidemiol; 2013 Oct; 37(5):732-6. PubMed ID: 23731550
[TBL] [Abstract][Full Text] [Related]
16. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.
Zheng Y; Jiang L; Hu Y; Xiao C; Xu N; Zhou J; Zhou X
BMC Cancer; 2017 Feb; 17(1):161. PubMed ID: 28241806
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of miR-299-5p inhibits the progression of hepatocellular carcinoma by targeting SIAH1.
Jiang X; Shen X
Bull Cancer; 2018 Oct; 105(10):873-883. PubMed ID: 30266288
[TBL] [Abstract][Full Text] [Related]
18. TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex.
Guo P; Ma X; Zhao W; Huai W; Li T; Qiu Y; Zhang Y; Han L
Oncogene; 2018 Jan; 37(4):478-488. PubMed ID: 28967907
[TBL] [Abstract][Full Text] [Related]
19. Stanniocalcin-1 Reduces Tumor Size in Human Hepatocellular Carcinoma.
Yeung BH; Shek FH; Lee NP; Wong CK
PLoS One; 2015; 10(10):e0139977. PubMed ID: 26469082
[TBL] [Abstract][Full Text] [Related]
20. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.
Patil MA; Gütgemann I; Zhang J; Ho C; Cheung ST; Ginzinger D; Li R; Dykema KJ; So S; Fan ST; Kakar S; Furge KA; Büttner R; Chen X
Carcinogenesis; 2005 Dec; 26(12):2050-7. PubMed ID: 16000397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
